WATERTOWN, Mass., July 22 /PRNewswire-FirstCall/ -- V.I. Technologies,
Inc. (Nasdaq: VITX) ("Vitex" or "the Company") announced today that the
Company will report its second quarter 2005 financial results before the U.S.
Financial Markets open on Wednesday, July 27, 2005. Following the
announcement, Vitex will hold a conference call at 9:00 a.m. Eastern time to
discuss the results and provide a corporate update on the Company's
development programs. Dr. Samuel K. Ackerman, Chairman and CEO, will lead the
call.
Date: Wednesday, July 27, 2005
Time: 9:00 a.m. Eastern time
Conference call numbers
Domestic: (800) 905-0392
International: (785) 832-2422
Please call between 8:50 and 8:55 a.m. and ask to be connected to the
Vitex conference call. A replay of the conference call will be available
until Friday, July 29, 2005, and can be accessed by dialing toll-free (888)
562-2849, and outside the U.S. (402) 220-7359.
About Vitex
Vitex is developing the next generation of anti-infective products. The
Company is engaged in the discovery and development of small molecule oral
drugs for the treatment of HIV and other major human viral diseases. Vitex's
proprietary discovery technologies and lead therapeutic candidate PA-457 focus
on novel targets in the virus life cycle, including virus fusion and virus
maturation. For more information on Vitex, please visit our web site at:
http://www.vitechnologies.com.
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the progress of clinical
development of PA-457 and the timing of results of clinical trials, the
execution of the Company's financing plans, the timely availability of new
products, market acceptance of the Company's products, the impacts of
competitive products and pricing, government regulation of the Company's
products, the Company's ability to complete product development collaborations
and other strategic transactions and other risks and uncertainties set forth
in the Company's filings with the Securities and Exchange Commission. These
risks and uncertainties could cause actual results to differ materially from
any forward-looking statements made herein.
CONTACT:
Samuel K. Ackerman, M.D.
Chairman and CEO
617-926-1551
sackerman@vitechnologies.com
SOURCE V.I. Technologies, Inc.
 back to top
Related links:
http://www.vitechnologies.com
CONTACT:
Samuel K. Ackerman, M.D., Chairman and CEO of
V.I. Technologies, Inc., +1-617-926-1551,
sackerman@vitechnologies.com
|
